{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:29:10Z","timestamp":1790152150734,"version":"4.0.1"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2014,6,4]],"date-time":"2014-06-04T00:00:00Z","timestamp":1401840000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0098336","type":"journal-article","created":{"date-parts":[[2014,6,4]],"date-time":"2014-06-04T20:26:54Z","timestamp":1401913614000},"page":"e98336","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":25,"title":["Immune Responses and Hypercoagulation in ERT for Pompe Disease Are Mutation and rhGAA Dose Dependent"],"prefix":"10.1371","volume":"9","author":[{"given":"Sushrusha","family":"Nayak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip A.","family":"Doerfler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy L.","family":"Porvasnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise D.","family":"Cloutier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richie","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken J.","family":"Valenzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland W.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry J.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,6,4]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2011.02.004","article-title":"Pompe disease: design, methodology, and early findings from the Pompe Registry","volume":"103","author":"BJ Byrne","year":"2011","journal-title":"Molecular Genetics and Metabolism"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"PS Kishnani","year":"2006","journal-title":"J Pediatr"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe&apos;s disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"HM van den Hout","year":"2003","journal-title":"Pediatrics"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ajmg.c.31316","article-title":"The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease","volume":"160","author":"E Lacana","year":"2012","journal-title":"American journal of medical genetics Part C, Seminars in medical genetics"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"PS Kishnani","year":"2010","journal-title":"Molecular genetics and metabolism"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ymgme.2010.08.009","article-title":"High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa","volume":"101","author":"JM de Vries","year":"2012","journal-title":"Mol Genet Metab"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"van Gelder CM, Hoogeveen-Westerveld M, Kroos MA, Plug I, van der Ploeg AT, <etal>et al<\/etal>.. (2014) Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease. Journal of inherited metabolic disease.","DOI":"10.1007\/s10545-014-9707-6"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"50336","DOI":"10.1074\/jbc.M409676200","article-title":"Conjugation of mannose 6-phosphate-containing oligosaccharides to acid alpha-glucosidase improves the clearance of glycogen in pompe mice","volume":"279","author":"Y Zhu","year":"2004","journal-title":"The Journal of biological chemistry"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s004399900075","article-title":"The frequency of lysosomal storage diseases in The Netherlands","volume":"105","author":"BJ Poorthuis","year":"1999","journal-title":"Human genetics"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/mt.2009.195","article-title":"Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease","volume":"18","author":"B Sun","year":"2010","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ymgme.2012.03.009","article-title":"Mapping the T helper cell response to acid alpha-glucosidase in Pompe mice","volume":"106","author":"S Nayak","year":"2012","journal-title":"Molecular genetics and metabolism"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0960-8966(99)00117-0","article-title":"Modulation of disease severity in mice with targeted disruption of the acid alpha-glucosidase gene","volume":"10","author":"N Raben","year":"2000","journal-title":"Neuromuscular disorders: NMD"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/mus.21291","article-title":"A novel mutation of the GAA gene in a Finnish late-onset Pompe disease patient: clinical phenotype and follow-up with enzyme replacement therapy","volume":"40","author":"MP Korpela","year":"2009","journal-title":"Muscle & nerve"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2006.09.010","article-title":"Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II","volume":"90","author":"T Okumiya","year":"2007","journal-title":"Molecular Genetics and Metabolism"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1172\/JCI62860","article-title":"Viral acute lower respiratory infections impair CD8+ T cells through PD-1","volume":"122","author":"JJ Erickson","year":"2012","journal-title":"The Journal of clinical investigation"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1128\/JVI.01693-10","article-title":"Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB\/c mice","volume":"85","author":"KL Stokes","year":"2011","journal-title":"Journal of virology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1172\/JCI40659","article-title":"Sphingosine kinase 1 and sphingosine-1-phosphate receptor 2 are vital to recovery from anaphylactic shock in mice","volume":"120","author":"A Olivera","year":"2010","journal-title":"The Journal of clinical investigation"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00000029","article-title":"Systemic anaphylaxis\u2014separation of cardiac reactions from respiratory and peripheral vascular events","volume":"190","author":"SB Felix","year":"1990","journal-title":"Research in experimental medicine Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3233\/BIR-2009-0533","article-title":"Inter-species differences in hematocrit to blood viscosity ratio","volume":"46","author":"N Nemeth","year":"2009","journal-title":"Biorheology"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Regnery C, Kornblum C, Hanisch F, Vielhaber S, Strigl-Pill N, <etal>et al<\/etal>.. (2012) 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy. Journal of inherited metabolic disease.","DOI":"10.1007\/s10545-012-9451-8"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ymthe.2005.04.024","article-title":"Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II","volume":"12","author":"LM Franco","year":"2005","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.ymgme.2010.11.020","article-title":"Bortezomib: a solution to the challange of antibodies in diseases treated with therapeutic proteins?","volume":"102","author":"PS Banugaria","year":"2011","journal-title":"Molecular Genetics and Metabolism"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease","volume":"14","author":"YH Messinger","year":"2012","journal-title":"Genet Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ymgme.2011.01.009","article-title":"Oral administration of recombinant human acid alpha-glucosidase reduces specific antibody formation against enzyme in mouse","volume":"103","author":"T Ohashi","year":"2011","journal-title":"Molecular Genetics and Metabolism"},{"key":"ref25","first-page":"1733","article-title":"Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Mol Ther","volume":"17","author":"O Cao","year":"2009"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1002\/emmm.201302859","article-title":"Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies","volume":"5","author":"DM Markusic","year":"2013","journal-title":"EMBO molecular medicine"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1073\/pnas.0912181107","article-title":"Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice","volume":"107","author":"D Verma","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1755-8417-1-6","article-title":"Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts","volume":"1","author":"M Cardone","year":"2008","journal-title":"PathoGenetics"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ymgme.2013.04.015","article-title":"A randomised, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of three dosing schedules of agalsidase alfa enzyme replacement therapy for Fabry disease","volume":"109","author":"DA Hughes","year":"2013","journal-title":"Molecular Genetics and Metabolism"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10545-012-9528-4","article-title":"Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment","volume":"36","author":"NJ Weinreb","year":"2013","journal-title":"Journal of inherited metabolic disease"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"e40776","DOI":"10.1371\/journal.pone.0040776","article-title":"The pharmacological chaperone AT2220 increases recombinant human acid alpha-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease","volume":"7","author":"R Khanna","year":"2012","journal-title":"PloS one"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/adt.2011.0370","article-title":"Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders","volume":"9","author":"KJ Valenzano","year":"2011","journal-title":"Assay and drug development technologies"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Elder ME, Nayak S, Collins SW, Lawson LA, Kelley JS, <etal>et al<\/etal>.. (2013) B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease. The Journal of pediatrics 163: 847\u2013854 e841.","DOI":"10.1016\/j.jpeds.2013.03.002"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Banugaria SG, Prater SN, McGann JK, Feldman JD, Tannenbaum JA, <etal>et al<\/etal>.. (2012) Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. Genetics in medicine: official journal of the American College of Medical Genetics.","DOI":"10.1038\/gim.2012.110"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.4161\/hv.21405","article-title":"Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease","volume":"8","author":"LP Cousens","year":"2012","journal-title":"Human vaccines & immunotherapeutics"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1074\/jbc.M112.438663","article-title":"Glycosylation-independent Lysosomal Targeting of Acid alpha-Glucosidase Enhances Muscle Glycogen Clearance in Pompe Mice","volume":"288","author":"JA Maga","year":"2013","journal-title":"The Journal of biological chemistry"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/mt.2013.282","article-title":"Sustained Correction of Motoneuron Histopathology Following Intramuscular Delivery of AAV in Pompe Mice","volume":"22","author":"MK Elmallah","year":"2014","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"R61","DOI":"10.1093\/hmg\/ddr174","article-title":"Pompe disease gene therapy","volume":"20","author":"BJ Byrne","year":"2011","journal-title":"Human molecular genetics"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0098336","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T15:19:02Z","timestamp":1597936742000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0098336"}},"subtitle":[],"editor":[{"given":"Reury F. P.","family":"Bacurau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,6,4]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,6,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0098336","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,4]]}}}